Objectives
INFLUENZA A, SECONDARY
The primary objectives of Part 1 were to evaluate the safety and reactogenicity of a single dose of mRNA-1010 (50 µg, 100 µg, and 200 µg) versus placebo and to evaluate the humoral immunogenicity of a single dose of mRNA-1010 against vaccine-matched influenza A and B strains at Day 29. The objectives of Part 2 were to evaluate the safety and reactogenicity of mRNA-1010 (25 µg, 50 µg, and 100 µg; primary) and to evaluate the humoral immunogenicity of mRNA-1010 and active comparator against vaccine-matched influenza A and B strains at Day 29 (primary and secondary).